HDAC6 and plasma cell myeloma: The third molecule, ACY-1215, was chosen not only for its potency and selectivity towards HDAC6 [26], but also because this compound is currently tested in a phase II clinical trial for multiple myeloma (clinicaltrails.gov identifier: NCT01323751) [26].